



 **Raymed Labs Ltd.**  
*Manufacturers of Allopathic Medicines*

CIN: L24111UP1992PLC014240

**REGISTERED OFFICE, HEAD OFFICE & FACTORY :**  
GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)  
e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com  
Tel. 0132-3242000

14<sup>th</sup> November, 2015

The Manager – Listing  
The Department of Corporate Services  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai – 400001

**BSE Scrip Code: 531207**

**Subject: Outcome of the Meeting of the Board of Directors**

Dear Sir,

This is to inform you that in the meeting of the Board of Directors held on Saturday, November 14, 2015 following Resolutions were passed:


1. The Board considered and approved the Unaudited Financial Results as per Clause 41 of the Listing Agreement for the quarter/half year ended September 30, 2015.
2. The Board took note of the Limited Review Report as per Annexure V of Clause 41 of the listing agreement as placed by the auditor of the company.

We hope you will find the same in order.

Kindly take the above information on your records.

Thanking you,

Sincerely,  
For **Raymed Labs Ltd.**



**Ajai Goyal**  
Managing Director

**DIN: 02636418**

Encl: as stated

Cc: **Ahmedabad Stock Exchange Limited**

*Life is Precious .....and Raymed cares*



# Raymed Labs Ltd.

**Manufacturers of Allopathic Medicines**

CIN: L24111UP1992PLC014240

**REGISTERED OFFICE, HEAD OFFICE & FACTORY :**  
GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

PART I							Rs. in Lacs
	Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months Ended	Year to Date Figures for Current Period Ended	Year to Date Figures for the Previous Year Ended	Previous Year Ended
		30-09-2015	30-06-2015	30-09-2014 in the Previous Year	30-09-2015	30-09-2014	31-03-2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1</b>	<b>Income from Operations</b>						
	(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-	-	-
	(b) Other Operating Income	-	-	-	-	-	-
	<b>Total Income from Operations (net)</b>	-	-	-	-	-	-
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	Changes in inventories of finished goods,						
	(c) work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee expenses & benefits	0.23	0.23	0.25	0.45	0.70	1.00
	(e) Depreciation and amortisation expense	-	-	-	-	-	-
	(f) Other expenses	0.67	0.56	2.17	1.23	2.40	2.99
	<b>Total Expenses</b>	<b>0.90</b>	<b>0.78</b>	<b>2.42</b>	<b>1.68</b>	<b>3.10</b>	<b>3.99</b>
<b>3</b>	<b>Profit/(Loss) from Operations before other Income, Finance costs and Exceptional Items (1-2)</b>	-0.90	-0.78	-2.42	-1.68	-3.10	-3.99
4	Other Income	0.54	0.54	0.54	1.08	1.08	2.16
<b>5</b>	<b>Profit/Loss from ordinary activities before finance costs and exceptional Items (3+4)</b>	<b>-0.36</b>	<b>-0.24</b>	<b>-1.88</b>	<b>-0.60</b>	<b>-2.02</b>	<b>-1.83</b>
6	Finance Costs	-	-	-	-	-	0.00
<b>7</b>	<b>Profit/Loss from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>-0.36</b>	<b>-0.24</b>	<b>-1.88</b>	<b>-0.60</b>	<b>-2.02</b>	<b>-1.83</b>
8	Exceptional Items	-	-	-	-	-	-
<b>9</b>	<b>Profit/Loss from Ordinary Activities before tax (7-8)</b>	<b>-0.36</b>	<b>-0.24</b>	<b>-1.88</b>	<b>-0.60</b>	<b>-2.02</b>	<b>-1.83</b>
10	Tax Expense	-	-	-	-	-	-
<b>11</b>	<b>Net Profit/ Loss from Ordinary Activities after Tax (9-10)</b>	<b>-0.36</b>	<b>-0.24</b>	<b>-1.88</b>	<b>-0.60</b>	<b>-2.02</b>	<b>-1.83</b>
12	Extraordinary Item (net of tax expense)	-	-	-	-	-	-
<b>13</b>	<b>Net Profit/ Loss for the period (11-12)</b>	<b>-0.36</b>	<b>-0.24</b>	<b>-1.88</b>	<b>-0.60</b>	<b>-2.02</b>	<b>-1.83</b>
17	Paid up Equity Share Capital (Face Value Rs.10/- per share)	427.35	427.35	427.35	427.35	427.35	427.35
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-
<b>19 i</b>	<b>Earning Per Share (before extraordinary items)</b>	<b>-0.008</b>	<b>-0.006</b>	<b>-0.044</b>	<b>-0.014</b>	<b>-0.047</b>	<b>-0.04</b>
<b>19 ii</b>	<b>Earning Per Share (after extraordinary items)</b>	<b>-0.008</b>	<b>-0.006</b>	<b>-0.044</b>	<b>-0.014</b>	<b>-0.047</b>	<b>-0.04</b>

*Life is Precious .....and Raymed cares*



# *Raymed Labs Ltd.*

**Manufacturers of Allopathic Medicines**

CIN: L24111UP1992PLC014240

**REGISTERED OFFICE, HEAD OFFICE & FACTORY :**  
GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

**e-mail :** raymedlabs@rediffmail.com **website :** www.raymedlabs.com

**Tel.** 0132-3242000

PART II							
	Particulars	3 Months Ended 30-09-2015	Preceding 3 Months Ended 30-06-2015	Corresponding 3 Months Ended 30-09-2014 in the Previous Year	Year to Date Figures for Current Period Ended 30-09-2015	Year to Date Figures for the Previous Year Ended 30-09-2014	Previous Year Ended 31-03-2015
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
1	Public Shareholding						
	- Number of shares	30,61,450	30,61,450	30,61,450	30,61,450	30,61,450	30,61,450
	- Percentage of shareholding	71.64%	71.64%	71.64%	71.64%	71.64%	71.64%
2	Promoters and promoter group Shareholding						
a)	Pledged/Encumbered						
	- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a% of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b)	Non-encumbered						
	- Number of Shares	12,12,050	12,12,050	12,12,050	12,12,050	12,12,050	12,12,050
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a% of the total share capital of the company)	28.36%	28.36%	28.36%	28.36%	28.36%	28.36%

B	INVESTOR COMPLAINTS	3 Months Ended (30/09/2015)
	Pending at the beginning of the quarter	NIL
	Received during the quarter	NIL
	Disposed off during the quarter	NIL
	Remaining unresolved at the end of the quarter	NIL

**Notes:**

- 1 The unaudited financial statements for the quarter ended on September 30, 2015 as reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 14, 2015. The information presented above is extracted from the financial statement.
- 2 EPS has been calculated in accordance with AS-20 issued by ICAI.
- 3 The Business of the Company falls under a single segment for the purpose of Accounting Standard As-17, issued by The Institute of Chartered Accountants of India.
- 4 Previous period/year figures have been regrouped/rearranged, wherever found necessary.
- 5 No investor complaints were pending in the beginning and end of the quarter ended September 2015.

**For Raymed Labs Limited**

**Ajai Goyal**  
Place: Saharanpur  
Date: 14-11-2015

*Life is Precious .....and Raymed cares*



# Raymed Labs Ltd.

**Manufacturers of Allopathic Medicines**

CIN: L24111UP1992PLC014240  
**REGISTERED OFFICE, HEAD OFFICE & FACTORY :**  
 GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)  
 e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com  
 Tel. 0132-3242000

### Statement of Assets and Liabilities

*Rs. in Lacs*

Particulars	6 months ended 30-09-2015	previous year ended 31-03-2015
	Unaudited	Audited
	<b>A EQUITY AND LIABILITIES</b>	
<b>1 Shareholders' Funds</b>		
(a) Share Capital	427.35	427.35
(b) Reserves and Surplus	-	-
(c) Money Received Against Share Warrants	-	-
<b>Sub-total - Shareholders' Funds</b>	<b>427.35</b>	<b>427.35</b>
<b>2 Share Application Money Pending Allotment</b>		
<b>3 Minority Interest</b>		
<b>4 Non-Current Liabilities</b>		
(a) Long-Term Borrowings		
(b) Deferred Tax Liabilities (net)		
(c) Other Long-Term Liabilities		
(d) Long-Term Provisions		
<b>Sub-total - Non-Current Liabilities</b>		
<b>5 Current Liabilities</b>		
(a) Short-Term Borrowings	198.60	199.60
(b) Trade Payables	-	-
(c) Other Current Liabilities	4.04	3.75
(d) Short-Term Provisions	-	-
<b>Sub-total - Current Liabilities</b>	<b>202.64</b>	<b>203.35</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>629.99</b>	<b>630.70</b>
<b>B ASSETS</b>		
<b>1 Non-Current Assets</b>		
(a) Fixed Assets	20.20	20.20
(b) Goodwill on Consolidation	-	-
(c) Non-current Investments	-	-
(d) Deferred Tax Assets (net)	-	-
(e) Long-term Loans and Advances	-	-
(f) Other Non-current Assets	-	-
<b>Sub-total - Non-Current Assets</b>	<b>20.20</b>	<b>20.20</b>
<b>2 Current Assets</b>		
(a) Current Investments	-	-
(b) Inventories	-	-
(c) Trade Receivables	2.49	2.49
(d) Cash and Cash Equivalents	0.16	0.49
(e) Short-term Loans and Advances	-	-
(f) Other Current Assets	6.10	7.10
<b>Sub-total - Current Assets</b>	<b>8.75</b>	<b>10.08</b>
<b>TOTAL - ASSETS</b>	<b>28.96</b>	<b>30.28</b>
<b>3 Profit and Loss Account</b>	<b>601.03</b>	<b>600.42</b>
<b>TOTAL APPLICATION OF FUNDS</b>	<b>629.99</b>	<b>630.70</b>

For Raymed Labs Limited

Ajai Goyal  
 Managing Director

Place: Saharanpur  
 Date: 14-11-2014

*Life is Precious .....and Raymed cares*



# A. KAY. MEHRA & CO.

C H A R T E R E D   A C C O U N T A N T S

114 ( BASEMENT ), MALL ROAD,  
KINGSWAY CAMP, DELHI-110009  
NEAR GTB NAGAR METRO STATION,  
Ph. No. : 011- 32965997, 9891295255  
E- Mail : akmca1969@gmail.com  
Website : www.akmca.in

## ANNEXURE V to Clause 41

To  
The Board of Directors  
Raymed Labs Limited


### Limited review Report for the quarter ended September 30, 2015

We have reviewed the accompanying statement of unaudited financial results of Raymed Labs Limited for the quarter and half year ended September 30, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed or that it contains any material misstatement.

For M/s. A Kay Mehra & Co.  
Chartered Accountants

  
(Deepak Suneja)  
(Partner)  
(Membership No. 501957)

Place : Delhi  
Date : November 14, 2015